Categories
Change Password!
Reset Password!
In COVID-19 patients receiving antibiotic treatment, dysbiosis of the gut microbiota triggers potentially fatal bloodstream infections.
According to the findings of a recent study, gut microbiome dysbiosis in antibiotic-treated COVID-19 people is related to microbial translocation and bacteremia. Researchers aimed to determine the link of gut microbiome dysbiosis with bacteremia and microbial translocation in SARS-CoV-2 infected patients who were on antibiotics. A total of 96 individuals infected with COVID-19 were included. From the electronic medical records, extraction of data comprising demographics, clinical outcomes, and laboratory findings was done.
Wherever possible, paired stool and blood samples were taken for the duration of the hospital stay. By conducting standardized interviews with patients or patient surrogates, the onset and cause of the symptoms were documented. Software programmes like REDCap 9.3.6 and EPIC EHR were used to gather the clinical data. Significant gut microbiome dysbiosis was also found in samples taken from participants at two distinct clinical locations, incorporating blooms of opportunistic pathogenic bacterial genera known to contain antimicrobial-resistant species.
Bacteria may translocate from the gut into the systemic circulation of SARS-CoV-2 infected subjects, according to evaluation of blood culture findings evaluation for secondary microbial bloodstream infections with linked microbiome data. These findings support the idea that gut-to-blood translocation of microorganisms following microbiome dysbiosis directly contributes to severe complications of COVID-19.
Nature Communications
Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia
Lucie Bernard-Raichon et al.
Comments (0)